Go Pro
→ Three companies about to leapfrog Nvidia [And transform the entire industry] (From Eagle Publishing) (Ad)tc pixel Free AOLS Stock Alerts
OTCMKTS:AOLS

Aeolus Pharmaceuticals (AOLS) Stock Price, News & Analysis

Compare

About Aeolus Pharmaceuticals Stock (OTCMKTS:AOLS)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
312,988 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

Receive AOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeolus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AOLS Stock News Headlines

Aeolus Pharmaceuticals Inc. (AOLS)
May 28, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/aols/sec-filings
AOLS Aeolus Pharmaceuticals, Inc.
August 28, 2024  |  seekingalpha.comhttps://seekingalpha.com/symbol/AOLS
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.tc pixel
September 4 at 1:00 AM  |  Paradigm Press (Ad)
SDCI.P:CA St. Davids Capital Inc.
July 20, 2024  |  seekingalpha.comhttps://seekingalpha.com/symbol/SDCI.P:CA
ASLN ASLAN Pharmaceuticals Limited
April 27, 2024  |  seekingalpha.comhttps://seekingalpha.com/symbol/ASLN
Aeolus Tyre Co Ltd (600469)
January 12, 2024  |  investing.comhttps://www.investing.com/equities/aeolus
Aeolus: Wind-mapping space laser is losing power
December 16, 2023  |  bbc.comB
Aeolus Announces Third Quarter Fiscal Year 2015 Financial Results
February 21, 2023  |  yahoo.comhttps://www.yahoo.com/entertainment/s/aeolus-announces-third-quarter-fiscal-110000633.html
See More Headlines

AOLS Stock Analysis - Frequently Asked Questions

Aeolus Pharmaceuticals Inc. (OTCMKTS:AOLS) issued its quarterly earnings results on Monday, August, 14th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $0.01 million for the quarter.

Shares of AOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aeolus Pharmaceuticals investors own include Myriad Genetics (MYGN), Nutra Pharma (NPHC), Titan Pharmaceuticals (TTNP), ADOMANI (ADOM), Agritek (AGTK) and

Company Calendar

Last Earnings
8/14/2017
Today
9/04/2026
Fiscal Year End
9/30/2026
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:AOLS
CIK
1261734
Web
www.aeoluspharma.com
Phone
(949) 481-9825
Fax
949-481-9829
Employees
4
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.92
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (OTCMKTS:AOLS) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Earth's biggest energy source: near Grand Canyon
The largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...
Behind the Markets | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...
Freedom Financial | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel